External validation in a multicenter dataset of 1245 type 2 diabetes patients with AKD supports the favorable outcomes
What injuries are people reporting in GLP-1 lawsuits
The good news is that there are several ways to address tightness concerns
Notably, these patients had already demonstrated willingness to pursue pharmacologic weight loss, indicating that the oral formulation may be influencing treatment choice even among experienced users, rather than reflecting delayed entry or newly established eligibility
In the SURPASS clinical trial program for type 2 diabetes, tirzepatide demonstrated A1c reductions of 1.9% to 2.4% and weight loss averaging 15 to 22 pounds, depending on the dose
Potential Effects on Fat Storage: Emerging research suggests GLP-1 medications may also influence how your body stores and processes fat, although this effect is less pronounced than their impact on appetite and calorie intake